EPLR 3/2019 (Vol. 3)

Editorial

Page 105 - 106

The Diversity of Drug Statutes Regarding Scientific Advances: How to Categorise a Culture Supernatant for Health Security Reasons

Laure Fourrier, Sylvain Perruche, Mathieu Guerriaud

Page 107 - 115

EU SPC Manufacturing Waiver Becomes Effective: What Can Industry Expect?

Philipp Cepl, Marco de Morpurgo, Chiara Perotti

Page 116 - 120

Recent Developments in the Regulation of 'Combination Products' Under European Law

Annabelle Bruyndonckx, Vladimir Murovec

Page 121 - 126

Timing is Everything: The CJEU on Genuine use of Pharmaceutical Trade Marks in Viridis Pharmaceutical

Judith Krens, Irenah S Klink

Page 127 - 131

CJEU Case C-387/18: Parallel Imports Shall not be Precluded on the Basis of a National Law Requirement for Identical ‘Registration Category’

Vicky N. Kriketou

Page 132 - 134

Jurisdiction

Page 135 - 137

New EU Pharmaceutical Law and Policy

Page 138